Trump Can Overturn Biden’s Socialist Healthcare Policies
TL/DR –
President Trump has directed Health and Human Services Secretary Robert F. Kennedy Jr to work with Congress to address government interference in the prescription drug market, including the “pill penalty” regulation. The article suggests that government price control programs, such as Medicare Part D, lead to unintended consequences, citing Europe as an example where drug price control policies have created shortages of prescription drugs and undermined the pharmaceutical industry. The writer argues that President Trump should pursue policies based on free market competition, transparency, and patient choice to lower healthcare costs, and reject government price control schemes.
President Trump Addresses Manipulation in Prescription Drug Market
President Trump has urged Health and Human Services Secretary Robert F. Kennedy Jr to collaborate with Congress on tackling government interference in the prescription drug market, focusing on eliminating the “pill penalty” regulation.
Reducing Governmental Control in Healthcare
The Trump administration and its allies are also urged to challenge Biden’s socialist healthcare agenda further. This includes limiting governmental control over Medicare Part D drugs, a result of the Inflation Reduction Act of 2022 that passed without a single Republican vote.
The Act allows the Department of Health and Human Services to compel drugmakers to offer certain products at discounted prices to the government for Medicare Part D. Non-compliance results in a 95 percent excise tax and loss of a significant patient market segment, as the details of the Act reveal.
The Impact of Drug Price Ceilings
Price caps on prescription drugs can lead to severe unintended consequences, as seen in Europe. European policies have caused prescription drug shortages and undermined the region’s pharmaceutical manufacturing sector and innovation. Implementing price controls discourages research and development, a lesson the U.S. should heed.
Pharmaceutical innovation is expensive, often taking over a decade and billions of dollars. Consequently, price caps reduce the revenue companies need to fund these investments, leading to fewer new drugs and fewer breakthroughs for diseases like cancer and Alzheimer’s, as research indicates.
Looking Towards a Free Market Healthcare Future
President Trump should continue to push for policies emphasizing free market competition, transparency, and increased patient choice to lower healthcare costs. This includes rejecting harmful policy ideas such as foreign reference pricing, which has been suggested by some in the administration.
The administration needs to focus on eliminating existing and future government price control schemes, thus leading America towards healthier future free from healthcare manipulation.
—
Read More US Economic News